Market Overview

CAR T Cell Therapy Market 2018-2028 - Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies - ResearchAndMarkets.com

Share:

The "CAR
T Cell Therapy Market Global Forecast by Regions, Targeted Antigens,
Clinical Trials/Study, Companies, and Celgene Corporation"

company profile has been added to ResearchAndMarkets.com's
offering.

CAR T Cell therapy market is expected to grow with a CAGR of over 46% in
the forecast period

Year 2017 has created new milestone for the oncology patients as FDA
approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T
cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in
the United States. These two approvals will certainly help to boost the
global CAR T cell therapy market as more players are looking for big
opportunities to enter the market place. At present over 200 CAR T
clinical trials are running or completed across various parts of the
world.

Rising numbers of adults and children developing cancer, increasing
government initiatives for promoting research for cell therapy in cancer
and rising number of clinical trials globally are some of the key
drivers for the global CAR T Cell therapy market; however high cost of
CAR T cell therapy treatment and regulatory challenges are key
inhibitors for this market.

This report studies the Global CAR T cell therapy market from 2 key view
points by CAR T cell therapy market and CAR T cell therapy studies.
Market segments are further studied by geographical regions and targeted
antigens whereas CAR T cell therapy studies by targeted antigens
globally and China specific. The report provides a complete analysis of
the key Growth Drivers and Challenges, SWOT analysis, market, and their
projections for the upcoming years (2028).

The report has been analyzed from 9 major viewpoints

1. Targeted Antigen - Global CAR T Cell Therapy Market

2. Regional CAR T Cell Therapy Market

3. Global - CAR T Cell Therapy Clinical Trials/Study

4. China CAR T Cells Clinical Trials Details

5. CAR T Cell Therapy SWOT Analysis

6. The Regulation in CAR T Cell Therapy

7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy
Market

8. Growth Drivers and Challenges

9. Key CAR T companies Initiatives and Financial Insight

Targeted Antigens - Global CAR T Cell Therapy Market & Forecast

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER2
  • MESO
  • EGFRvII
  • Others

Regional CAR-T Cell Therapy Market & Forecast

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Global - CAR T Cell Therapy Clinical Trials/Study

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • MESO
  • EGFRvII

China CAR T Cells Clinical Trials Details

  • By Cities CAR T Cells Clinical Trials
  • CD19 Directed CAR T Cells Clinical Trials
  • Non-CD19 Directed CAR T Cells Clinical Trials
  • Solid Tumors CAR T Cells Clinical Trials

The Regulation in CAR T Cell Therapy

  • United States
  • European Union
  • China

IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

  • Venture Capital Investment
  • Initial Public Offerings
  • Strategic Partnerships/Deals
  • Key CAR T Technology Deals

Key Companies covered in this report are

  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad

For more information about this company profile visit https://www.researchandmarkets.com/research/372757/car_t_cell?w=4

View Comments and Join the Discussion!